{"schema_version":"1.0","type":"article","title":"This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body","url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket-en.md","lang":"en","date":"2026-08-13","publish_at":"2026-08-13T10:30:00+08:00","updated_at":"2026-08-13","category":"商業分析系列","topic":"商業分析系列","tags":["Intelligene","RNA delivery","oligonucleotide therapeutics","siRNA","ASO","extracellular vesicles","LNP","extrahepatic delivery","Taiwan biotech"],"summary":"Oligonucleotide therapeutics are moving from sequence design to extrahepatic delivery. Intelligene is using EV and LNP platforms to target the lung and airways, testing whether RNA medicines can truly reach disease sites beyond the liver.","key_points":[],"facts":[],"sections":["01 | Oligonucleotide Therapeutics Have Moved from Scientific Promise to Commercial Reality","02 | The Liver Was the First Orbit, Not the Final Destination","03 | Markets Are Repricing RNA Platforms by Organ-Level Difficulty and Degree of Validation","04 | Intelligene Is Building a Nanorocket Inside the Human Body","05 | Extracellular Vesicles: The Real Barrier Is CMC, Not Imagination","06 | Australia Connects a Taiwan-Built Platform to an International Clinical Pathway","07 | The Market Will Now Look for Lift-Off Data","Conclusion | In the Second Half of Oligonucleotide Therapeutics, Value Lies in Reaching the Target","References","Disclaimer"],"references":[{"title":"[Alnylam, Inceptive sign up to $2 billion AI drug discovery deal","source":"Reuters]","date":"","url":"https://www.reuters.com/legal/litigation/alnylam-inceptive-sign-up-2-billion-ai-drug-discovery-deal-2026-06-03/"},{"title":"[The Leading RNAi Therapeutics Company","source":"Alnylam]","date":"","url":"https://www.alnylam.com/"},{"title":"[Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B","source":"GSK]","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/"},{"title":"[Intelligene — Core Technology]","source":"","date":"","url":"https://www.intelli-gene.com/en/research"},{"title":"[Intelligene — News and Media]","source":"","date":"","url":"https://www.intelli-gene.com/en/news"}],"images":[{"alt":"Figure 1 | The first half of oligonucleotide therapeutics is sequence design; the second half is delivery beyond the liver.","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-01.png"},{"alt":"Figure 2 | Commercial RNA medicines, hepatitis B functional-cure data, and extrahepatic delivery are reshaping the small-RNA opportunity.","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-02.png"},{"alt":"Figure 3 | Organ-level delivery difficulty is beginning to reprice RNA platform companies.","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-03.png"},{"alt":"Figure 4 | Intelligene is using lung and airway programs to build an EV and LNP RNA delivery platform.","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-04.png"},{"alt":"Figure 5 | Intelligene's next valuation variables include preclinical data, IND progress, Phase 1 entry, CMC execution, and international partnerships.","url":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-05.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-13）。This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body。https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-13-intelligene-rna-delivery-nanorocket.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}